Gulf War Illness Clinical Trial
Official title:
Confirmation of Diet as a Treatment for Gulf War Illness
This clinical trial aims to confirm previous findings from a smaller study which demonstrated significant improvements in all symptoms among veterans with Gulf War Illness after one month on the dietary intervention. The main objectives of this study are: 1) to confirm previous findings of treatment response to the diet in a larger and more diverse group; 2) to examine how changes in the nervous system may be the reason for improvement; and 3) to identify markers which change in the blood after one month on the diet. Participants will have baseline measures collected and then will be randomized into the intervention or wait-listed control group, which they will follow for one month before being reassessed.
Status | Recruiting |
Enrollment | 160 |
Est. completion date | December 30, 2025 |
Est. primary completion date | August 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 75 Years |
Eligibility | Inclusion Criteria: - Males and Females of all races and ethnicities who are =75 yrs of age - Served in the 1990-1991 Persian Gulf War - Fulfill both Center for Disease Control (CDC) and Kansas definitions of Gulf War Illness - Stable medication regimen for =1 month and willing to keep medications and supplements stable throughout study participation Exclusion Criteria: - Recent substance use disorder (past year) - Unwilling to stop using alcohol, tobacco (including vaping) and/or marijuana; or unwilling to change diet - Diagnosed seizure disorder or severe asthma requiring past hospitalization - Currently taking medication which affects glutamatergic or GABAergic neurotransmission (but can work with their physician to wean off of these medications prior to participating) |
Country | Name | City | State |
---|---|---|---|
United States | Boston University | Boston | Massachusetts |
United States | Nova Southeastern University | Fort Lauderdale | Florida |
United States | American University | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
American University | Boston University, Georgetown University, Massachusetts General Hospital, Nova Southeastern University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total Symptom Score | This measure computes the number of symptoms being experienced in this widespread chronic pain condition, and also computes a score based on severity of each symptom. The raw symptom score ranges from 0-32, and the symptom severity score ranges from 0-96, with higher scores indicative of worse outcomes. | 1-month | |
Primary | Patient Global Impression of Change Scale (PGIC) | The PGIC is a self-report measure of the amount of change experienced from the treatment using a 7-point scale with the following options: very much worse, much worse, a little worse, no change, a little better, much better, very much better. | 1-month | |
Secondary | McGill Pain Questionnaire | This pain measure inquires about types of pain sensation ranked on a scale of 0 to 3, with a total score from 0-45. Higher scores indicate worse pain. | 1-month | |
Secondary | Chalder Fatigue Score | The Chalder Fatigue Scale measures the extent and severity of fatigue. It is a scale with answers to each question based on both bimodal and likert scores, resulting in a total score of 0-11 and 0-33, with higher scores indicating more fatigue. | 1-month | |
Secondary | Veterans RAND 36 Item Health Survey (VR-36) | This is a 36-item survey used to measure health related quality of life, to estimate disease burden and to evaluate disease-specific impact on general and selected populations. The items on the questionnaire correspond to eight principal health domains including general health perceptions, physical functioning, role limitations due to physical and emotional problems, bodily pain, energy-fatigue, social functioning and mental health. This results in physical and mental health component quality of life scores, each scored from 0-100, with higher scores indicating a better quality of life. | 1-month | |
Secondary | Brief Irritability Questionnaire (BITe) | This short questionnaire assesses anger and irritability with 5 questions ranked on a 6-point scale. Higher scores indicate more irritability. | 1-month | |
Secondary | Center for Epidemiological Studies Depression Scale (CES-D) | This is a 20-item measure that asks individuals to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms. | 1-month | |
Secondary | Generalized Anxiety Disorder Scale (GAD-7) | A brief questionnaire with 7 questions which measure generalized anxiety disorder. The GAD-7 score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of 'not at all', 'several days', 'more than half the days', and 'nearly every day', respectively, and adding together the scores for the seven questions. Total scores range from 0-21, with higher scores indicating more anxiety. | 1-month | |
Secondary | PTSD Checklist for DSM-5 (PCL-5) | The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. The self-report rating scale is 0-4 for each symptom, reflecting a change from 1-5 in the DSM-IV version. Rating scale descriptors are the same: "Not at all," "A little bit," Moderately," "Quite a bit," and "Extremely." A total symptom severity score (range - 0-80) can be obtained by summing the scores for each of the 20 items, with higher total scores indicating a higher probability of having PTSD. | 1-month | |
Secondary | Cognitive Testing | Cognitive function will be measured using computerized cognitive testing software and one administered exam in-person. An overall score, called a neurocognitive index, is computed as the average of 5 domain scores, with higher scores equating to better cognitive function. | 1-month | |
Secondary | Dolorimetry | Pain threshold will be measured using a dolorimeter, where pressure is applied to 18 points on the body that are typically tender in widespread chronic pain conditions. The participant will report when pain starts and the kilograms of pressure will be recorded. These will be averaged over the 18 sites, with higher scores indicative of having a higher (better) pain threshold. | 1-month | |
Secondary | Biophotonic scanner | A biophotonic scanner will be used to assess long-term carotenoid intake from the diet. This is a painless test where an infared light is shone through the index finger. This results in a numeric score from 0-800, with a higher score indicative of higher dietary carotenoid intake. | 1-month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04254627 -
TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset
|
Phase 1 | |
Terminated |
NCT02011542 -
Probiotic (VSL #3) for Gulf War Illness
|
Phase 2/Phase 3 | |
Recruiting |
NCT03078530 -
Probiotic (Visbiome) for Gulf War Illness
|
Phase 2/Phase 3 | |
Recruiting |
NCT04058275 -
"Immunomodulation in GWI (Phlebotomy)"
|
||
Recruiting |
NCT04255498 -
Understanding GWI: Integrative Modeling
|
Phase 1 | |
Completed |
NCT02782780 -
Cognitive Behavioral Therapy for Insomnia for Gulf War Illness
|
N/A | |
Recruiting |
NCT02983734 -
D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS)
|
Phase 2 | |
Recruiting |
NCT05972291 -
Mechanisms of Gulf War Illness
|
N/A | |
Recruiting |
NCT04046536 -
rTMS in Alleviating Pain and Co-Morbid Symptoms in Gulf War Veterans Illness (GWVI)
|
N/A | |
Recruiting |
NCT04182659 -
Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms
|
N/A | |
Recruiting |
NCT05377242 -
Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI
|
N/A | |
Recruiting |
NCT05736146 -
Validating Gulf War Illness Blood Biomarkers
|
||
Not yet recruiting |
NCT05820893 -
Resistant Potato Starch to Alleviate GWI
|
Phase 2 | |
Terminated |
NCT01846182 -
Research Examining Gulf War Illness in Our Nations Service Members
|
Phase 2 | |
Active, not recruiting |
NCT05252949 -
OEA for Targeting Lipid Metabolism in GWI
|
N/A | |
Completed |
NCT02378025 -
Treating Chronic Pain in Gulf War Illness
|
N/A | |
Completed |
NCT02865460 -
Coenzyme Q10 Phase III Trial in Gulf War Illness
|
Phase 3 | |
Completed |
NCT02909686 -
Effects of Botanical Microglia Modulators in Gulf War Illness
|
N/A | |
Completed |
NCT01291758 -
Exercise in Gulf War Illness (GWI)
|
||
Completed |
NCT01011348 -
Q10 for Gulf War Veterans
|
N/A |